Streptococcus pneumoniae type 19A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

DB10298ApprovedInvestigationalVaccinesInactivated Pneumococcal Vaccine

Streptococcus pneumoniae type 19a capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 19A individually conjugated to... The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

First approval
United States, 2010 · European Union, 2022
Also known as
Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine
Brand names
  • Capvaxive
  • Prevnar 13
  • Prevnar 20
  • Vaxneuvance

Resolves to

Compound
UNIIB970MQT365
Clinical / RWD
RxNorm901624

What you can answer from here — as of August 01, 2026

32Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
27Marketed productsAcross 5 countries and 6 labellers
Sign in

Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 19A capsular polysaccharide diphtheria CRM197 protein conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In